EUVIMEDEUVIMED entdecken
BeobachtungsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial

Ali Al-Kassab-Córdova iD, Anna B C Humphreys iD, Camila Olarte Parra iD, Maria Feychting iD, Anthony A Matthews iD

American Journal of Epidemiology · 2025

DOI: 10.1093/aje/kwaf183 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Ali Al-Kassab-Córdova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen, Antineoplastic Agents, Hormonal, Aromatase Inhibitors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Forte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benchmarking an observational analysis against a randomized trial increases our confidence in the use of observational data for causal inference. The Breast International Group (BIG 1-98) randomized trial compared the effect of letrozole and tamoxifen on the risk of death in postmenopausal women with hormone receptor–positive breast cancer. We designed a target trial that aimed to ask the same question as the one asked in BIG 1-98 and emulated it in Swedish registry data. The primary results from our observational analysis showed an increased risk of death in those who initiated aromatase inhibitors compared with tamoxifen [5-year risk difference = 2.5% (95% CI, 0.2-4.6)], which was discordant to the results from BIG 1-98. However, estimates were more closely aligned when our observational analysis was restricted to nonusers of opioids or antidepressants [5-year risk difference = −0.9 (95% CI, −4.2 to 2.0)]. In conclusion, when benchmarking an observational analysis against a trial, alignment of eligibility criteria with the index trial is not always sufficient and further study population restrictions may be required to address unmeasured confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTamoxifenAntineoplastic Agents, HormonalAromatase InhibitorsNitrilesTriazolesHumansFemalePostmenopauseBenchmarkingLetrozoleAgedRandomized Controlled Trials as TopicMiddle AgedSweden

Stichwörter der Autor:innen

benchmarkingbreast cancerclinical trialobservational studiestarget trial emulation

Substanzen

TamoxifenAntineoplastic Agents, HormonalLetrozoleAromatase InhibitorsNitrilesTriazoles

Autor:innen und Institutionen

  • Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Universidad San Ignacio de Loyola, Lima, Peru.

ORCID-Profile: Ali Al-Kassab-Córdova, Anna B C Humphreys, Camila Olarte Parra, Maria Feychting, Anthony A Matthews

Förderung

  • Forte

Zitieren

APA

Al-Kassab-Córdova, A., Humphreys, A. B. C., Olarte Parra, C., Feychting, M., & Matthews, A. A. (2025). Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwaf183

Vancouver

Al-Kassab-Córdova A, Humphreys ABC, Olarte Parra C, Feychting M, Matthews AA. Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwaf183

BibTeX
@article{AlKassabCrdova2025,
  author = {Al-Kassab-Córdova, Ali and Humphreys, Anna B C and Olarte Parra, Camila and Feychting, Maria and Matthews, Anthony A},
  title = {Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial},
  journal = {American Journal of Epidemiology},
  year = {2025},
  doi = {10.1093/aje/kwaf183}
}
Kostenlos starten →